27
Jan

Pfizer, a deal-minded drugmaker sitting on billions in cash, is more interested in acquiring near-market assets than investing in long-term projects, counting on a blockbuster oncology collaboration to keep its early-stage pipeline afloat.

…read more

Source: Pfizer’s hunting for safe M&A bets, not high-risk pipeline deals

    

0 No comments